SAN DIEGO , Jan. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 at 9:00 a.m. Pacific Time ( 12:00 p.m. Eastern Time ). The webcast can be accessed... Read More

Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating... Read More

Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The pilot program is based... Read More

SAN DIEGO , Jan. 9, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2024 following the close of market on Thursday, February 6 , 2025. On the same day, at 1:30 pm Pacific Time ( 4:30 pm Eastern Time ) Jacob Thaysen , PhD, Chief Executive Officer, and Ankur Dhingra , Chief Financial Officer, will host a conference call with analysts, investors,... Read More

Software upgrade advances complete workflow solutions New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X, and enable newly released Illumina Single-Cell Prep SAN DIEGO , Jan. 7, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based... Read More

SAN DIEGO , Dec. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 43 rd Annual J.P. Morgan Healthcare Conference on January 14, 2024 Presentation at 9:00am Pacific Time ( 12:00pm Eastern Time ) immediately followed by a Q&A Session to begin at approximately 9:20am Pacific Time ( 12:20pm Eastern Time ) The webcast can be accessed... Read More

Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry Technology to be used in Illumina's next-generation sequencing (NGS) products AMSTERDAM , Dec. 4, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index and... Read More

The latest solution to enable comprehensive genomic profiling of tumors will be presented at the annual meeting of the Association of Molecular Pathology Customer-led research and presentations at the conference will deliver the latest evidence and education in tumor profiling SAN DIEGO , Nov. 19, 2024 /PRNewswire/ --... Read More

SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Wolfe Research 2024 Healthcare Conference on November 20, 2024 Fireside chat at 6:20am Pacific Time ( 9:20am Eastern Time ) 7 th Annual Evercore HealthCONx Conference on December 3, 2024 Fireside chat at 10:20am Pacific Time ( 1:20pm Eastern Time ) For each... Read More

Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis Core Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024 Core Illumina GAAP diluted EPS of $4.03 and non-GAAP diluted EPS of $1.14 for Q3 2024 Lowered fiscal year 2024 Core Illumina revenue guidance to decline ~3% from fiscal year 2023; expect Q4 2024 Core Illumina revenue of... Read More

New, groundbreaking technology delivers Illumina's most comprehensive genome yet; early results from Broad Clinical Labs demonstrate a highly simplified workflow, ultra-long phasing, high-resolution insights into complex genomic variation, and enhanced long-range information Illumina and customers will also showcase new details on complete proteomics solution and latest data on Fluent single-cell technology SAN DIEGO , Oct.... Read More

Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO , Oct. 9, 2024 /PRNewswire/ - - Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based... Read More

SAN DIEGO , Oct. 7, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2024 following the close of market on Monday, November 4 , 2024. On the same day, at 1:30 pm Pacific Time ( 4:30 pm Eastern Time ) Jacob Thaysen , PhD, Chief Executive Officer, and Ankur Dhingra , Chief Financial Officer, will host a conference call with analysts, investors, and other... Read More

SAN DIEGO , Oct. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that after 11 years of service, Charles "Chuck" Dadswell will step down as General Counsel and Secretary on October 3 . Dadswell has agreed to remain an Illumina employee, serving as an advisor to CEO Jacob Thaysen and the Board of Directors, through March 31, 2025 . Scott Davies... Read More

SAN DIEGO , Sept. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL. Today's judgment confirms Illumina's longstanding view that the European Commission exceeded its authority by asserting... Read More

TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims The 500+ gene biomarker test advances access to localized precision oncology for patients SAN DIEGO , Aug. 27, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a... Read More

Company poised to accelerate revenue growth into high single digits over next three years, enabled by core genomics portfolio Innovations to enable development of transformative applications using multiomics Illumina to offer higher quality insights to customers, helping them improve the overall end-to-end workflow experience and lower cost Delivering double digit to teens non-GAAP diluted earnings per share growth 2025-2027... Read More

Core Illumina revenue of $1.09 billion for Q2 2024, down 6% from Q2 2023 (down 6% on a constant currency basis) and up 3% from Q1 2024 Core Illumina GAAP operating margin of 40.5% and non-GAAP operating margin of 22.2% for Q2 2024 Core Illumina GAAP diluted earnings per share of $0.41 and non-GAAP diluted earnings per share of $1.09 for Q2 2024 Lowered fiscal year 2024 Core Illumina revenue guidance to decline 2% to 3% (down... Read More

Delivers Illumina's flagship oncology products on its most powerful sequencers to enable comprehensive genomic profiling at greater scale and at lower overall costs for customers SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today... Read More

SAN DIEGO , July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24 , the company will present a Strategy Update on Tuesday, August 13, 2024 starting at 8:00am Pacific Time . The event will feature presentations by members of Illumina's executive team and conclude with a Q&A session. Webcast Details The webcast can be accessed through the Events & Presentations section of Illumina's... Read More

SAN DIEGO , July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24 , the company will issue results for the second quarter 2024 following the close of market on Tuesday, August 6 , 2024. On the same day, at 1:30 pm Pacific Time ( 4:30 pm Eastern Time ) Jacob Thaysen , Chief Executive Officer, and Ankur Dhingra , Chief Financial Officer, will host a conference call with analysts,... Read More

Accessible, highly scalable single-cell technology expands Illumina's multiomics capabilities SAN DIEGO , July 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that effective today it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology. "The addition of Fluent BioSciences to Illumina will... Read More

GRAIL spin-off complete; GRAIL to begin regular way trading as "GRAL" on June 25 Illumina to issue second quarter 2024 results on August 6 ; leadership to present Strategy Update on August 13 SAN DIEGO , June 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced plans to divest GRAIL, and GRAIL is... Read More

Latest version includes a prebuilt pangenome capturing more genetic diversity, reducing ancestry bias, and improving accuracy SAN DIEGO , June 11, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of DRAGEN™ v4.3, the latest version of... Read More

SAN DIEGO , June 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemistry, XLEAP-SBS ™ , into all reagents for its NextSeq ™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments. "We are excited to deliver for our NextSeq 1000/2000 customers improved sequencing with faster run times,... Read More

"When-issued" trading expected to begin on or about June 12, 2024 Record date for distribution of GRAIL shares will be June 13, 2024 Distribution date for GRAIL shares anticipated to be June 24, 2024 SAN DIEGO , June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its Board of Directors has approved the spin-off of GRAIL. GRAIL is anticipated to spin off from Illumina on June 24, 2024 , and has... Read More

Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma SAN DIEGO , June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment... Read More

Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome approach for MRD SAN DIEGO , May 29, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and... Read More

SAN DIEGO , May 28, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its fifth annual Corporate Social Responsibility (CSR) Report. The report highlights the company's ongoing commitments and progress made in 2023 toward advancing human health by... Read More

Ms. Richo brings more than 30 years of global legal, compliance, and regulatory experience to Illumina's Board SAN DIEGO , May 20, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that Anna Richo has joined the company's Board of Directors following shareholder approval of the director slate at the company's... Read More

SAN DIEGO , May 15, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Bernstein's 40 th Annual Strategic Decisions Conference on May 29, 2024 Fireside chat at 6:00am Pacific Time ( 9:00am Eastern Time ) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com . A replay will be... Read More

GRAIL to host Capital Markets Day on May 13 , 2024 SAN DIEGO , May 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has publicly filed a Form 10 registration statement with the U.S. Securities and Exchange Commission ("SEC"), in connection with its intended divestiture of GRAIL. A version of this registration statement was submitted to the SEC last December as required. The Form 10 includes... Read More

SAN DIEGO , May 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: RBC 2024 Global Healthcare Conference on May 14, 2024 Fireside chat at 5:30am Pacific Time ( 8:30am Eastern Time ) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com . A replay will be posted on Illumina's... Read More

Core Illumina revenue of $1.06 billion for Q1 2024, down 2% from Q1 2023 (down 2% on a constant currency basis) Core Illumina GAAP operating margin of 11.0% and non-GAAP operating margin of 20.6% for Q1 2024 Reiterating fiscal year 2024 Core Illumina revenue guidance that is approximately flat compared to 2023 and a Core Illumina non-GAAP operating margin for fiscal year 2024 of approximately 20% Consolidated revenue of... Read More

SAN DIEGO , April 12, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC). While this does not mean the method of divestment has been finalized, the company is pleased to reach an agreement with the EC on specific divestment options as it represents an... Read More

Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO , April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He... Read More

SAN DIEGO , April 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2 , 2024. On the same day, at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) Jacob Thaysen , Chief Executive Officer, and Joydeep Goswami , Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference... Read More

Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis) Shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023 GAAP diluted loss per share of $(1.11) for Q4 2023, compared to GAAP diluted loss per share of $(0.89) for Q4 2022 Non-GAAP diluted... Read More

SAN DIEGO , Jan. 9, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2023 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 at 9:00am Pacific Time ( 12:00pm Eastern Time ). The webcast can be accessed through the Investor Info section of Illumina's... Read More

SAN DIEGO , Jan. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen). This collaboration will be the first relating to the development of Illumina's novel molecular... Read More

SAN DIEGO , Jan. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the fourth quarter and full year 2023 following the close of market on Thursday, February 8 , 2024. On the same day, at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) Jacob Thaysen , Chief Executive Officer, and Joydeep Goswami , Chief Financial Officer and Chief Strategy and Corporate Development Officer,... Read More

AGD delivered ~86,000 whole genomes in 2023, including a unique diverse ancestry cohort Expanded pharma engagement enhances AGD's ability to develop multiomic datasets SAN DIEGO , Jan. 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned... Read More

SAN DIEGO , Dec. 19, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 42 nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 Presentation at 9:00am Pacific Time ( 12:00pm Eastern Time ) immediately followed by a Q&A Session to begin at approximately 9:20am Pacific Time ( 12:20pm Eastern Time ) The webcast can be accessed... Read More

SAN DIEGO , Dec. 17, 2023 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL. The divestiture will be executed through a third-party sale or capital markets transaction, consistent with the European Commission's divestiture order, with the goal of finalizing the terms by the end of the second quarter of 2024. On December 15 , the U.S. Fifth Circuit Court of Appeals issued its... Read More

SAN DIEGO , Dec. 11, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has confidentially submitted a draft registration statement on Form 10 related to its potential divestiture of GRAIL to the U.S. Securities and Exchange Commission, pursuant to an order Illumina received from the European Commission (EC) directing the company to divest GRAIL. Submission of this registration statement is an important next step in... Read More

SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Evercore ISI 6 th Annual HealthCONx Conference on November 28, 2023 Fireside Chat at 7:50am Pacific Time ( 10:50am Eastern Time ) Piper Sandler 35th Annual Healthcare Conference on November 29, 2023 Fireside chat at 8:30am Pacific Time ( 11:30am Eastern Time ) The... Read More

Program aims to address key barriers to genomic sequencing in-country SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for... Read More

Welcomed new CEO Jacob Thaysen , Ph.D., who started with Illumina on September 25, 2023 With respect to GRAIL, continue to proceed quickly: retained advisors and preparing for sale and capital markets transaction options for GRAIL, including filing a Form 10, in accordance with the European Commission's divestiture order; a Board special committee has been established to expedite decisions; in parallel, ongoing appeals... Read More

TSO 500 ctDNA Version 2 delivers faster turnaround time, greater analytical sensitivity, more streamlined workflow, further enabling precision medicine. SAN DIEGO , Nov. 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its... Read More

SAN DIEGO , Oct. 13, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), has received an order from the European Commission (EC) directing the company to divest GRAIL. Receipt of the order is an important next step in evaluating divestiture options for GRAIL. Illumina is committed to resolving all issues regarding GRAIL in a timely manner, with the objective of achieving the maximum value for shareholders and the best outcome... Read More

SAN DIEGO , Oct. 11, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) posted a stewardship-focused presentation for investors on the Events & Presentations section of its investor relations website, investor.illumina.com , on Wednesday, October 11, 2023 . Members of Illumina's Board of Directors and senior management may use this presentation during meetings with investors. About Illumina Illumina is improving human health... Read More

SAN DIEGO , Oct. 5, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2023 following the close of market on Thursday, November 9 , 2023. On the same day, at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) Jacob Thaysen , Chief Executive Officer, and Joydeep Goswami , Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a... Read More

SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has appointed Jacob Thaysen , Ph.D., senior vice president of Agilent Technologies and president of its Life Sciences and Applied Markets Group, as Chief Executive Officer, effective September 25, 2023 . Mr. Thaysen's extensive background and... Read More

SAN DIEGO , Aug. 28, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Morgan Stanley 21st Annual Global Healthcare Conference on September 11, 2023 Fireside chat at 9:55am Pacific Time ( 12:55pm Eastern Time ) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com . A replay will... Read More

SAN DIEGO , Aug. 17, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of a new office and state-of-the-art Illumina Solutions Center in Bengaluru, India . Illumina's expansion comes after 16 years of working closely with the company's... Read More

SAN DIEGO , Aug. 11, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its vice president of investor relations will be speaking at the following investor conference: UBS MedTech, Tools and Genomics Summit 2023 on August 17, 2023 Fireside chat at 9:00am Pacific Time ( 12:00pm Eastern Time ) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com . A... Read More

SAN DIEGO , Aug. 9, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Dr. Steven Barnard , Illumina's Vice President and Head of Global Advanced Science, will serve as its next Chief Technology Officer (CTO), effective immediately. Dr. Alex Aravanis , who held the position of CTO, will be departing Illumina to pursue another opportunity outside... Read More

Revenue of $1.18 billion for Q2 2023, up 1% from Q2 2022 (up 3% on a constant currency basis) and up 8% from Q1 2023 Shipped 109 NovaSeq X instruments in Q2 2023; boosting our supply capacity to more than 390 instruments for fiscal year 2023 GAAP diluted loss per share of $(1.48) for Q2 2023, compared to GAAP diluted loss per share of $(3.40) for Q2 2022, which included $609 million in legal contingencies Non-GAAP diluted... Read More

SAN DIEGO , July 25, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar's suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products. The agreement will result in an unprecedented offering of... Read More

SAN DIEGO , July 18, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2023 following the close of market on Wednesday, August 9 , 2023. On the same day, at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) Charles Dadswell , Interim Chief Executive Officer and General Counsel, and Joydeep Goswami , Chief Financial Officer and Chief Strategy and Corporate... Read More

Alliance aims to accelerate therapeutic development and expand the diversity of genomic data through inclusion of more samples from currently underrepresented ancestries SAN DIEGO , July 18, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with... Read More

2023 marks five years of industry-leading DRAGEN software offered by Illumina SAN DIEGO , July 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the latest version of DRAGEN™ software for analysis of next-generation sequencing... Read More

SAN DIEGO , June 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has accepted the resignation of Francis deSouza as Illumina's Chief Executive Officer and as a Director, effective Sunday, June 11 . Charles Dadswell , Senior Vice President and General Counsel, has been named interim CEO while the Board of... Read More

SAN DIEGO , June 5, 2023 /PRNewswire/ -- Illumina Inc . (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its annual Corporate Social Responsibility (CSR) Report , highlighting the company's commitment to human health, and the progress made by its environmental, social, and... Read More

Stephen P. MacMillan , Hologic CEO, named non-executive Chair of Illumina's Board Scott B. Ullem , CFO of Edwards Lifesciences, also named to Board SAN DIEGO , June 2, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of governance changes consistent with the goal of enhancing long-term shareholder value. The Board has elected two new... Read More

Published findings demonstrate PrimateAI-3D's ability to improve genetic risk prediction and drug target discovery using primate DNA and advanced artificial intelligence SAN DIEGO , June 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the new PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts with unprecedented accuracy... Read More

SAN DIEGO , May 31, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will host its third annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:00 am Pacific Time ( 12:00 pm Eastern Time ), Monday, June 12, 2023 . Francis deSouza, Chief Executive Officer, Joydeep Goswami , Chief Financial Officer and Chief Strategy and Corporate Development Officer, Aimee Hoyt... Read More

Data also shows that current standard-of-care testing for cancer patients falls short in multiple ways SAN DIEGO , May 30, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of the latest data on the impact of comprehensive genomic profiling... Read More

Illumina shareholders re-elect eight of nine Illumina directors SAN DIEGO , May 25, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that based on the preliminary results of its 2023 Annual Meeting, Illumina shareholders have voted to elect eight of nine Illumina director nominees – Francis deSouza, Robert Epstein , MD, Frances Arnold , PhD,... Read More

ST. LOUIS , May 24, 2023 /PRNewswire/ -- Pluton Biosciences, a startup leveraging the power of microbes to create cost-effective innovative solutions that address sustainability challenges facing agriculture, announces the close of a $16.5 M Series A funding round. The round was co-led by Illumina Ventures and RA Capital, with participation from existing investors Fall Line Capital, The Grantham Foundation, and First In... Read More

Board Chair John Thompson issues letter to Illumina shareholders ahead of the company's Annual Meeting on May 25, 2023 , at 10:00 am Pacific Time ( 1:00 pm Eastern Time ) Illumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina's director nominees For more information, visit www.IlluminaForward.com SAN DIEGO , May 18, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA... Read More

SAN DIEGO , May 16, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today recognized the progress and impact of genomic technologies on pathogen preparedness and response. Following the boost in sequencing infrastructure and capabilities driven by the COVID-19... Read More

Illumina's director nominees bring deep commercial, scientific and business experience from leading organizations including Microsoft, Symantec, and Medco-UBC Leading proxy advisory firm ISS has recommended Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein Icahn's associates bring ZERO relevant experience and ZERO independence Illumina requests shareholders to vote the WHITE proxy... Read More

SAN DIEGO , May 12, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Institutional Shareholder Services ("ISS"), a leading independent proxy voting and corporate governance advisory firm, recommends Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein . Illumina's Annual Meeting is scheduled to be held on... Read More

Illumina is led by its world-class Board members and has best-in-class governance practices Carl Icahn's recently released "plan" demonstrates his lack of understanding of both Illumina and the genomics industry Illumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina's director nominees Annual Meeting will be held virtually on May 25, 2023 , at 10:00 am Pacific Time ( 1:00 pm Eastern Time )... Read More

The Future Is Bright genomic literacy initiative expands to Japan , South Korea and United Arab Emirates SAN DIEGO , May 2, 2023 /PRNewswire/ - - Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced outcomes from its annual The Future Is Bright campaign, a monthlong... Read More

Strong NovaSeq TM X shipments drove solid Illumina first quarter results; company commits to grow Core Illumina non-GAAP operating margins to 27%[1] in 2025 Announces more than $100 million in annualized cost savings Carl Icahn's campaign is spreading false information Carl Icahn's unqualified nominees are potentially harmful to Illumina's core business, if elected Illumina requests shareholders to vote the WHITE proxy card... Read More

Revenue of $1.09 billion for Q1 2023, up 1% from Q4 2022; down 11% from Q1 2022 (down 9% on a constant currency basis) GAAP diluted EPS of $0.02 for Q1 2023, compared to GAAP diluted EPS of $0.55 for Q1 2022 Non-GAAP diluted EPS of $0.08 for Q1 2023, compared to non-GAAP diluted EPS of $1.07 for Q1 2022 Reiterating fiscal year 2023 consolidated revenue guidance of 7% to 10% growth from 2022, including Core Illumina revenue... Read More

SAN DIEGO , April 20, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today urged shareholders to vote in favor of Illumina's slate of highly qualified director nominees. It also announced that its Annual Meeting will be held virtually on May 25, 2023 , at 10:00 am Pacific Time ( 1:00 pm Eastern Time ). Illumina's Board of Directors urges shareholders to... Read More

SAN DIEGO , April 12, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received the international privacy certification of six of its cloud-based informatics programs. The certification, ISO/IEC 27701, recognizes that Illumina implements,... Read More

Series of studies will focus on genetic drivers of cardiovascular disease, and how data can improve care, especially in underserved communities SAN DIEGO , April 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Henry Ford Health, a not-for-profit health... Read More

From genomics pioneer to global leader, the company ushers in the Genome Era of personalized health for all SAN DIEGO , April 5, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today begins a monthlong celebration of its 25th anniversary. A quarter-century... Read More

SAN DIEGO , April 4, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2023 following the close of market on Tuesday, April 25 , 2023. On the same day, at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) Francis deSouza, Chief Executive Officer, and Joydeep Goswami , Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a... Read More

Strong demand drives record orders SAN DIEGO , April 4, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has already exceeded more than 200 orders for its revolutionary NovaSeq X sequencing system in the first quarter of 2023. The orders... Read More

SAN DIEGO , April 3, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it will appeal the Federal Trade Commission's ("FTC") decision ordering the unwinding of Illumina's acquisition of GRAIL. Illumina intends to file a petition for review promptly with a US Court of Appeals and will seek expedited treatment of the appeal. The FTC's order to unwind the acquisition will be automatically stayed pending... Read More

SAN DIEGO , March 30, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today filed its preliminary proxy statement with the Securities and Exchange Commission, which contains important information for shareholders. The activist investor Carl Icahn has nominated three of his associates to stand for election to the Board of Directors at Illumina's 2023 Annual Meeting... Read More

Storage Veteran Appointments Bring Diverse Technical Expertise to Help Lead Implementation of Industry Standards for DNA Data Storage SAN DIEGO / Mar 29, 2023 / Business Wire / The DNA Data Storage Alliance, a SNIA Technology Affiliate, formed in 2020 by Illumina, Inc. (NASDAQ: ILMN), Microsoft (Nasdaq: MSFT), Twist Bioscience Corporation (NASDAQ: TWST) and Western Digital (NASDAQ: WDC) to create and promote an interoperable... Read More

As demand for clinical next-generation sequencing grows, Illumina Connected Insights enables user to streamline data interpretation and report generation to inform precision care SAN DIEGO , March 27, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today... Read More

SAN DIEGO , March 24, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, issued the following statement in response to a letter from Carl Icahn dated March 24, 2023 : Directors and Officers (D&O) insurance and corporate indemnification are standard for Delaware companies, and support directors in making decisions in the best interests of shareholders. All major... Read More

Illumina's plan will maximize shareholder value Illumina is engaged with regulators to define GRAIL's path forward as expeditiously as possible Icahn's director nominees do not add value to the Board and will damage Illumina's core business SAN DIEGO , March 20, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued the following response to Carl Icahn's... Read More

Early customer data reinforces accuracy and flexibility of novel long-read technology, unlocking access to challenging, low DNA input samples SAN DIEGO , March 14, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first product based on... Read More

SAN DIEGO , March 13, 2023 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, confirmed today that it has received notice from Icahn Partners LP and certain of its affiliates of their intention to nominate three candidates—two current Icahn employees, Jesse Lynn and Andrew Teno , and one former Icahn employee, Vincent Intrieri—for election to the Board of Directors... Read More

Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry SAN DIEGO , March 2, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the expansion of a strategic partnership... Read More

SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 43rd Annual Cowen Health Care Conference on March 7, 2023 Fireside chat at 6:50am Pacific Time ( 9:50am Eastern Time ) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com . A replay will be posted on... Read More

Carrier previously became the first life insurer to offer access to the Galleri test through a pilot in 2022 BOSTON , Feb. 23, 2023 /PRNewswire/ -- Today, John Hancock , a unit of Manulife (NYSE: MFC), announced it will expand access to GRAIL's Galleri ® multi-cancer early detection test to eligible life insurance customers participating in the John Hancock Vitality PLUS program, a significant milestone in John Hancock's... Read More

New data on NovaSeq X Plus and workflow insights on Illumina Complete Long Reads unveiled at AGBT HOLLYWOOD, Fla. , Feb. 8, 2023 /PRNewswire/ - - Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first NovaSeq X Plus system was recently delivered to the Broad... Read More

Revenue of $1.08 billion for Q4 2022, down 10% from Q4 2021, and down 7% on a constant currency basis Revenue of $4.58 billion for fiscal year 2022, up 1% from fiscal year 2021, and up 3% on a constant currency basis GAAP diluted loss per share of $(0.89) for Q4 2022, compared to GAAP diluted earnings per share of $0.71 for Q4 2021 Non-GAAP diluted earnings per share of $0.14 for Q4 2022, compared to non-GAAP diluted... Read More

SAN DIEGO , Feb. 1, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami has been appointed Chief Financial Officer, effective immediately. Goswami previously served as Illumina's Chief Strategy and Corporate Development Officer and interim Chief Financial Officer. As CFO, Goswami will be responsible for the Company's financial... Read More

SAN DIEGO , Jan. 10, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2022 following the close of market on Tuesday, February 7 , 2023. On the same day, at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) Francis deSouza, Chief Executive Officer, and Joydeep Goswami , Chief Strategy and Corporate Development Officer and Interim Chief Financial... Read More

Whole-genome sequencing of 35,000 de-identified, diverse genomic DNA samples will begin this month SAN DIEGO , Jan. 9, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Nashville Biosciences LLC , a wholly owned subsidiary of Vanderbilt University Medical... Read More

SAN DIEGO , Dec. 19, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41 st Annual J.P. Morgan Healthcare Conference on January 9, 2023 Presentation at 3:45pm Pacific Time ( 6:45pm Eastern Time ) immediately followed by a Q&A Session to begin at approximately 4:05pm Pacific Time ( 7:05pm Eastern Time ) The webcast can be accessed... Read More

As of December 9, 2022 Illumina awarded highest score from S&P Dow Jones Indices in Life Sciences Tools & Services Sector Illumina received leadership score with an A- from CDP SAN DIEGO , Dec. 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today... Read More